CD8A and diffuse large B-cell lymphoma: In addition, differences in dynamics between CAR‐T designs, i.e. axicabtagene ciloleucel (axi‐cel) and tisagenlecleucel (tisa‐cel), have been observed using scRNA‐seq analyses: whereas expansion of proliferative CD8 TEM CAR‐T was observed in DLBCL patients treated with tisa‐cel, more heterogeneous populations were predominant in responders treated with axi‐cel [30, 31].